One Federal St.//Boston, MA 02110-1726//United States
Tony Chan advises clients on public and private company mergers and acquisitions (M&A), private equity, growth equity, and venture capital transactions, as well as on corporate governance, joint ventures and corporate finance. Tony’s clients include global strategic buyers and sellers as well as financial sponsors and their portfolio companies in the life science, healthcare, investment management, technology, and video game sectors. He also regularly advises on complex international and cross-border transactions.
Tony serves as an adjunct professor at Georgetown Law School where he has taught Takeovers, Mergers and Acquisitions since 2015. He is also involved in the community, serving on the boards of the Arlington Arts Center and the Harvard Law School Association of DC.
Tony also maintains an active pro bono practice, serving as counsel to a number of nonprofit organizations, including Aequitas, APAI Vote, Rebuilding Together Philadelphia, the Philadelphia Film Society, and the Harvard Asian Alumni Alliance, in addition to a number of charter schools, including Rocketship Education.
Tony has been recognized for his life sciences and M&A work by a number of notable publications, including The Legal 500 US, Law360, IFLR1000, and Legal Media Group. In particular, Law360 highlighted his work in navigating the complex life sciences industry and key partnership negotiations between biotechnology and drug companies.
Represented South Korea-based Mirae Asset Global Investments in a $500 million financing of Impossible Foods, a company that develops plant-based substitutes for meat products with a much smaller environmental impact
Represented Stripes, a leading growth equity investor, in a Series B investment in Verbit, a provider of a transcription and captioning platform leveraging artificial intelligence to generate detailed speech-to-text files
Represented Stripes in a $150 million financing of Snyk, a company that helps developers organizations find and fix vulnerabilities in their code
Represented Stripes in a $60 million financing of ScaleFactor, an automated finance, tax and accounting platform.
Represented Stripes in a $32 million Series C Preferred Stock financing of FullStory, a developer of software tools designed to capture customer experience data
Represented Stripes in multiple financings of Remitly, an online international payments company, including in hte most recent $220 million dollar Series E financing
Represented Stripes in a $25 million Series B financing of BacklotCars, an online marketplace for automotive sales
Represented Stripes in a $30 million Series B financing of HyperScience, a company that creates AI-centered enterprise solutions for automating work
Represented Stripes in a $15 million financing of Remine which offers real estate intelligence to agents through its platform which analyzes property records, transaction history, consumer data and delivers opportunities on an intuitive user interface
Represented Stripes in a $53 million financing of Sift Sciences, the leading provider of fraud prevention and risk management solutions using real-time machine learning
Represented Turtle Beach Corporation, a global gaming accessory manufacturer based in San Diego, California, in its acquisition of ROCCAT, a developer of innovative, award-winning gaming mice, keyboards and other accessories
Represented Glade Brook Capital Partners in a $50 million Series I Preferred Share investment in Zomato Media, an online platform for restaurant discovery and delivery
Represented Glade Brook Capital Partners in a $450 million investment in Miss Fresh, an e-commerce company that delivers fresh produce in 20 Chinese cities
Represented Smash Ventures Management in its investments in Epic Games, the publisher of Fortnite, NOBULL, a footwear, apparel and accessory brand, and Manscaped
Represented companies in the video game industry in a wide variety of matters, including licensing, distribution, development, supply, manufacturing, co-promotion, sponsorship, e-sports and influencer agreements as well as with respect to IP, data protection and regulatory compliance.
Represented North America Science Associates, Inc., the first independent company in the world to focus solely on testing medical device materials for safety, in its sale of a majority interest to ArchiMed
Represented Celgene Corporation on its acquisition of Avila Therapeutics for up to $925 million, and investments in biotechnology companies, including Jounce, Juno, Nurix, Sutro BioPharma, Forma, Oncomed, and Epizyme
Represented Ipsen in connection with its acquisition of global oncology assets from Merrimack Pharmaceuticals for up to $1 billion
Represented Ferring Pharmaceuticals on its purchases of Cytokine PharmaSciences and Controlled Therapeutics and its acquisitions of Lysteda from Xanodyne Pharmaceuticals, DDAVP from Sanofi, Milprosa from Teva Women’s Health and orthobiologic product candidates from BioSurface Engineering Technologies
Represented Kain Capital in its acquisition of occupational medicine clinics, including ProCare Work Injury Center, an clinic located in southern California
Represented R-Pharm in its acquisition of Ixempra from Bristol-Myers Squibb
Represented Global X, a New York-based sponsor of thematic exchange-traded funds, in a joint venture with Tokyo-based Daiwa Securities Group, Japan’s second largest brokerage house, and Daiwa Asset Management to expand access to intelligent outcome-oriented ETFs for Japanese investors and a related $120 million convertible note investment
Represented Wasmer, Schroeder & Company, LLC, a fixed-income investment manager, in its sale to The Charles Schwab Corporation
Represented South Korea-based Mirae Asset Global Investments in its acquisition of Global X Management Company, a sponsor of thematic, income and international exchange-traded funds
Represented Pretium Capital Management in its acquisition of Valcour Capital Management
Represented Fifth Street CLO Management in its sale of Fifth Street CLO Management to Newstar Financial
Represented Marble Point Credit Management in its acquisition of American Capital CLO Management
Represented Guggenheim Investments in its acquisition of Accretive Asset Management
*Matters were handled prior to joining Morgan Lewis.
Awards and Affiliations
Recommended, Healthcare: life sciences, The Legal 500 US (2020)
Recommended, M&A/corporate and commercial: Commercial deals and contracts, The Legal 500 US (2019)
Rising Star, IFLR1000 Financial and Corporate (2017, 2019, 2020)
Rising Star, IFLR1000 United States (2018–2020)
Next Generation Lawyer, Life Sciences, The Legal 500 US (2017)
Rising Star, Life Sciences, Law360 (2016)
Rising Star, Corporate/M&A, Legal Media Group (2015, 2016)